Partial agonist/antagonist properties of androstenedione and 4-androsten-3β,17β-diol

被引:43
作者
Chen, F [1 ]
Knecht, K [1 ]
Leu, C [1 ]
Rutledge, SJ [1 ]
Scafonas, A [1 ]
Gambone, C [1 ]
Vogel, R [1 ]
Zhang, H [1 ]
Kasparcova, V [1 ]
Bai, C [1 ]
Harada, S [1 ]
Schmidt, A [1 ]
Reszka, A [1 ]
Freedman, L [1 ]
机构
[1] Merch Res Lab, Dept Mol Endocrinol, West Point, PA 19486 USA
关键词
endogenous androgen receptor binding; partial AR agonist/antagonist; MDA-MB-453; cells; LNCaP cells; AR K-d;
D O I
10.1016/j.jsbmb.2004.04.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Androgens play important endocrine roles in development and physiology. Here, we characterize activities of two "Andro" prohormones, androstenedione (A-dione) and 4-androsten-3beta,17beta-diol (A-diol) in MDA-MB-453 (MDA) and LNCaP cells. A-dione and A-diol, like cyproterone acetate, were partial agonists of transfected mouse mammary tumor virus (MMTV) and endogenous prostate-specific antigen (PSA) promoters. Different from bicalutamide but similar to CPA, both are inducers of LNCaP cell proliferation with only mild suppression of 5alpha-dihydrotestosterone (DHT)-enhanced cell growth. Like bicalutamide and cyproterone acetate, A-dione and A-diol significantly antagonized DHT/R1881-induced PSA expression by up to 30% in LNCaP cells. Meanwhile, in MDA cells, EC(50)s for the MMTV promoter were between 10 and 100 nM. Co-factor studies showed GRIN as most active for endogenous androgen receptor (AR), increasing MMTV transcription by up to five-fold, without substantially altering EC(50)s of DHT, A-dione or A-diol. Consistent with their transcriptional activities, A-dione and A-diol bound full-length endogenous AR from MDA or LNCaP cells with affinities of 30-70 nM, although binding to expressed ligand-binding domain (LBD) was greater than or equal to20-fold weaker. In contrast, DHT,R1881, and bicalutamide bound similarly to LBD or aporeceptor. Together, these data suggest that A-dione and A-diol are ligands for AR with partial agonist/antagonist activities in cell-based transcription assays. Binding affinities for both are most accurately assessed by AR aporeceptor complex. In addition to being testosterone precursors in vivo, either may impart its own transcriptional regulation of AR. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:247 / 257
页数:11
相关论文
共 39 条
  • [1] The role of antiandrogen monotherapy in the treatment of prostate cancer
    Anderson, J
    [J]. BJU INTERNATIONAL, 2003, 91 (05) : 455 - 461
  • [2] Physiology and molecular genetics of 17 beta-hydroxysteroid dehydrogenases
    Andersson, S
    Moghrabi, N
    [J]. STEROIDS, 1997, 62 (01) : 143 - 147
  • [3] Anabolic-androgenic steroid therapy in the treatment of chronic diseases
    Basaria, S
    Wahlstrom, JT
    Dobs, AS
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (11) : 5108 - 5117
  • [4] EFFECTS OF ANTIANDROGENS ON TRANSFORMATION AND TRANSCRIPTION ACTIVATION OF WILD-TYPE AND MUTATED (LNCAP) ANDROGEN RECEPTORS
    BERREVOETS, CA
    VELDSCHOLTE, J
    MULDER, E
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1993, 46 (06) : 731 - 736
  • [5] Antiandrogens: selective androgen receptor modulators
    Berrevoets, CA
    Umar, A
    Brinkmann, AO
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2002, 198 (1-2) : 97 - 103
  • [6] Oral andro-related prohormone supplementation: Do the potential risks outweigh the benefits?
    Broeder, CE
    [J]. CANADIAN JOURNAL OF APPLIED PHYSIOLOGY-REVUE CANADIENNE DE PHYSIOLOGIE APPLIQUEE, 2003, 28 (01): : 102 - 116
  • [7] Hsp90 reaches new heightsConference on the Hsp90 Chaperone Machine
    Avrom J Caplan
    Sophie Jackson
    David Smith
    [J]. The EMBO Reports, 2003, 4 (2) : 126 - 130
  • [8] ANDROGEN RECEPTOR - AN OVERVIEW
    CHANG, CS
    SALTZMAN, A
    YEH, SY
    YOUNG, WJ
    KELLER, E
    LEE, HJ
    WANG, CH
    MIZOKAMI, A
    [J]. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 1995, 5 (02): : 97 - 125
  • [9] Selective androgen receptor modulators
    Chengalvala, M
    Oh, T
    Roy, AK
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (01) : 59 - 66
  • [10] Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells
    Cleutjens, CBJM
    Steketee, K
    VanEekelen, CCEM
    VanderKorput, JAGM
    Brinkmann, AO
    Trapman, J
    [J]. ENDOCRINOLOGY, 1997, 138 (12) : 5293 - 5300